Skip to main content
. 2012 Jun;56(6):3224–3231. doi: 10.1128/AAC.05966-11

Table 2.

Clinical characteristics of patients with bloodstream infection caused by MDR and non-MDR P. mirabilis strainsb

Characteristic No (%) of patients
P value
MDR P. mirabilis group (n = 36) Non-MDR P. mirabilis group (n = 63)
Demographics
    Male sex 25 (69.4) 37 (58.7) 0.28
    Age >65 years 14 (38.8) 40 (63.5) 0.01
Comorbidities
    Solid tumor 14 (38.9) 17 (26.9) 0.21
    Hematological malignancy 4 (11.1) 6 (9.5) 0.80
    Liver disease 6 (16.7) 8 (12.7) 0.58
    Chronic renal failure 15 (41.7) 10 (15.9) 0.004
    Diabetes 10 (27.8) 14 (22.2) 0.53
    Charlson index ≥3 17 (47.2) 32 (50.8) 0.73
    Immunosuppressive therapy 8 (22.2) 22 (34.9) 0.18
Epidemiological category
    HCA BSI detected ≥48 h postadmission 29 (80.5) 53 (84.1) 0.65
    HCA BSI detected <48 h postadmission 5 (13.9) 6 (9.5) 0.50
    Community-acquired BSI 2 (5.5) 4 (6.3) 0.87
Clinical presentation
    Source of infection
        Central venous catheter 0 4 (6.3) 0.12
        Abdominal cavity 3 (8.3) 2 (3.2) 0.26
        Lower respiratory tract 1 (2.8) 2 (3.2) 0.91
        Surgical wound 4 (11.1) 1 (1.6) 0.03
        Urinary tract 19 (52.8) 28 (44.4) 0.42
        Unknown 12 (33.3) 28 (44.4) 0.27
    Shock 8 (22.2) 22 (34.9) 0.18
    APACHE III score (median [range])a 38 (10–71) 45 (3–118) 0.07
Inadequate initial antimicrobial therapy 14 (38.8) 7 (11.1) 0.001
Outcomes
    Treatment failure after the first 72 h 20 (55.5) 23 (36.5) 0.06
    21-day mortality 18 (50) 12 (19.1) 0.001
    Median (range) post-BSI hospital stay (days) for patients discharged alive 34 (8–129) 14 (2–105) 0.001
a

Calculated on the basis of chart data relative to the 24 h following BSI onset. When data were missing for one variable, that variable was assigned a value of 0 indicating that it was within normal limits. If more than one variable was missing, the case was excluded from the study.

b

Data are expressed as number (%) unless otherwise stated. Abbreviations: BSI, bloodstream infection; HCA, health care associated (as defined in Materials and Methods); MDR, multidrug resistant.